Table of contents

  • Progressive Supranuclear Palsy - Executive Insights - Progressive Supranuclear Palsy: Executive Insights (US/EU5/China ) - Roche
    • Progressive Supranuclear Palsy  | Executive Insights | US/EU5/China | March-2021

Author(s): Ruchita Kumar, Ph.D.; Anamika Ghosh, Ph.D.

Ruchita Kumar, M.Pharm., Ph.D., is a manager on the CNS/Ophthalmology Disorders team at DRG, part of Clarivate. Her specialties are migraine and Alzheimer’s disease. She has worked on a variety of opportunity assessment and market intelligence projects involving the preparation of disease narratives, epi-based forecasts, and building brand performance reports across different therapy areas. She holds a Ph.D. in the design and development of modified-release dosing forms of antidiabetic drugs from the University Institute of Pharmaceutical Sciences at Panjab University in Chandigarh, India.

Anamika Ghosh, M.Sc., Ph.D., is a manager on the Oncology team at DRG, part of Clarivate. She has expertise in various solid and hematological malignancies and immune-oncology drug classes, such as immune checkpoint inhibitors and CAR T-cell therapies. As a Ph.D. and postdoctoral fellow at the International Centre for Genetic Engineering and Biotechnology (ICGEB), Dr. Ghosh studied host-pathogen interactions during Mycobacterium tuberculosis and Dengue virus infections. She received her Ph.D. in life sciences from ICGEB and an M.Sc. in biomedical sciences from the University of Delhi.